Today: 12 May 2026
Palantir Stock Today: Why PLTR Is on Watch as Pentagon AI Spending Meets a Valuation Test
21 April 2026
2 mins read

Palantir Stock Today: Why PLTR Is on Watch as Pentagon AI Spending Meets a Valuation Test

NEW YORK, April 21, 2026, 09:30 EDT

  • Palantir ended Monday’s session at $145.89, slipping 0.34%. Early Tuesday, the stock was quoted higher in premarket action, according to market data.
  • Pentagon budget specifics for fiscal 2027 are set for release Tuesday, with investors zeroing in after the $1.5 trillion defense request spotlighted AI, missile defense, and command software.
  • Morgan Stanley’s Sanjit Singh and his team still see strong fundamentals for Palantir, but they flag valuation and political risk as the biggest hurdles for the stock.

Palantir Technologies shares rebounded in premarket U.S. trading Tuesday after a modest drop in the previous session. The stock finished Monday at $145.89, off 0.34%, but after hours ticked above $146. Investors are watching for new cues on defense spending out of Washington.

The immediate story? Palantir’s not behaving like your average software stock right now—it’s acting more like a defense-AI play, riding the wager that government money will keep chasing AI tools for parsing data, spotting threats, and speeding up decisions. Eyes now turn to the Pentagon’s fuller fiscal 2027 budget breakdown, due out Tuesday.

Earlier in the month, Reuters said President Donald Trump’s fiscal 2027 defense plan comes in at $1.5 trillion—a jump that would mark the steepest annual increase in U.S. defense outlays since World War Two. That sum factors in money for Golden Dome, the missile-defense shield, which carries a projected cost of $185 billion.

Palantir appears to have an inside track on that cash. Back in March, Reuters said the Pentagon intends to designate Palantir’s Maven AI system as a “program of record”—Pentagon-speak for locking in a dedicated spot in its budget and securing more reliable funding. Reuters

Virginia Burger, senior defense policy analyst at the Project on Government Oversight, described Palantir’s Maven Smart System as landing “as permanent a position as a program can get” inside the Defense Department, she told DefenseScoop. Equity investors pick up on that kind of talk—even if the contract money is still just potential for now. DefenseScoop

The Golden Dome angle complicates things further. According to Reuters, Anduril and Palantir are teaming up on the software side of the missile shield, while Lockheed Martin, RTX, and Northrop Grumman entered the picture earlier as prime contractors. That puts Palantir shoulder to shoulder with traditional defense players—but focused on software and data, not hardware.

Wall Street’s interest hasn’t faded. Morgan Stanley analyst Sanjit Singh and his team pointed to Palantir’s “fundamentals remain exceptionally strong”—highlighting U.S. momentum, bigger customers, and margins, according to Barchart. Over at TipRanks, Singh maintained his Hold rating and a $205 target. Barchart.com

Palantir’s latest numbers were tough to top. For the fourth quarter of 2025, the company posted revenue of roughly $1.41 billion—a 70% jump over last year. U.S. commercial sales soared 137%, while U.S. government revenue climbed 66%, based on MarketWatch’s breakdown of the results.

Palantir’s next update is around the corner. The company plans to release first-quarter earnings after the U.S. market shuts on May 4, with a webcast set for 5 p.m. ET.

Still, valuation remains the sticking point. Barchart’s market screen has Palantir sitting at steep sales and earnings multiples—investors are shelling out plenty for every dollar of revenue and profit here. Any letdown in Pentagon budget news, or delays on contract timing, and the stock could struggle to absorb even a mild miss.

Political risk is back in focus. Over the weekend, Palantir’s 22-point summary of CEO Alex Karp and Nicholas Zamiska’s The Technological Republic ran into fresh controversy. Business Insider flagged how the post fueled renewed arguments about AI weapons and national service. UK lawmakers, The Guardian noted, voiced concern around Palantir’s public-sector contract work.

Tuesday’s setup is tight. Investors are pressing for signs that Palantir’s defense-AI pitch is showing up as real, lasting budget commitments—headlines alone won’t cut it. The growth angle is clear, but so is the premium on the shares.

Stock Market Today

  • Wall Street Slides as AI Stocks Falter and Oil Prices Rise Amid Iran Conflict
    May 12, 2026, 5:23 PM EDT. Wall Street paused its record-setting rally as AI stocks declined and oil prices climbed amid tensions with Iran. The S&P 500 dropped 0.2% from its previous high, while the Nasdaq slipped 0.7%. Dow Jones Industrial Average rose slightly by 56 points. Significant losses hit chipmakers: Intel fell 6.8%, Micron Technology 3.6%, trimming strong year-to-date gains. South Korea's Kospi also dropped 2.3%, spooked by potential AI profit redistribution. Brent crude surged 3.4% to $107.77 a barrel due to Strait of Hormuz restrictions from the Iran war. Rising oil costs worsened U.S. inflation, surpassing forecasts, with Treasury yields climbing to 4.45%. Investors anticipate the Federal Reserve may maintain or hike interest rates amid persistent inflation concerns.

Latest article

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

12 May 2026
Ernexa Therapeutics shares jumped 58.5% to $11.43 Tuesday after renewed investor focus on its preclinical ovarian-cancer therapy ERNA-101, following a May 11 investor event. Trading volume reached about 18.85 million shares. The company reported $8.3 million in cash as of April 30, less than needed for its 12-month plan, and may use an at-the-market stock sale to raise funds.
UnitedHealth Stock Climbs as Investors Reprice the Turnaround, Not Just the Latest Headline

UnitedHealth Stock Climbs as Investors Reprice the Turnaround, Not Just the Latest Headline

12 May 2026
UnitedHealth shares climbed 3.1% to $396.45 Tuesday after unveiling a new Optum Rx fee-based pricing model and raising 2026 profit guidance. The company reported Q1 revenue of $111.7 billion and adjusted earnings of $7.23 per share. Management said fundamentals are improving but described the turnaround as ongoing. Investors responded to both the PBM overhaul and stronger earnings outlook.
BuzzFeed Stock Nearly Doubles as Byron Allen Deal Buys Time, Not a Clean Turnaround

BuzzFeed Stock Nearly Doubles as Byron Allen Deal Buys Time, Not a Clean Turnaround

12 May 2026
BuzzFeed shares jumped 97% to about $1.44 Tuesday after Byron Allen’s family office agreed to buy 40 million new shares at $3 each, securing 52% control. Only $20 million is due in cash at closing, with the rest as a five-year promissory note. BuzzFeed reported Q1 revenue down 12.4% to $31.6 million and a net loss of $15.1 million. The company warned of “substantial doubt” about its ability to continue operating.
Oil Price Today: Brent Drops Below $95 as U.S.-Iran Talks Test the Market’s Biggest Risk
Previous Story

Oil Price Today: Brent Drops Below $95 as U.S.-Iran Talks Test the Market’s Biggest Risk

Beyond Meat Stock Is Back Above $1 as BYND Rally Tests Wall Street’s Doubts
Next Story

Beyond Meat Stock Is Back Above $1 as BYND Rally Tests Wall Street’s Doubts

Go toTop